A case report of pneumomediastinum in a COVID-19 patient treated with high-flow nasal cannula and review of the literature: Is this a “spontaneous” complication?

Anna Cancelliere1 | Giada Procopio1 | Maria Mazzitelli1 | Elena Lio1 | Maria Petullà2 | Francesca Serapide1 | Maria Chiara Pelle1 | Chiara Davoli1 | Enrico Maria Trecarichi1 | Carlo Torti1 | The IDTM UMG COVID-19 Group

1Infectious and Tropical Disease Unit, Department of Medical and Surgical Sciences, “Magna Graecia” University of Catanzaro, Catanzaro, Italy
2Radiology Unit, Department of Medical and Surgical Sciences, “Magna Graecia” University of Catanzaro, Catanzaro, Italy

Abstract
Oxygen support with high-flow nasal cannula (HFNC) is gentler than mechanical ventilation and may provide significant benefits, but more studies are needed to investigate the efficacy and safety of different respiratory supports in patients with COVID-19 pneumonia.

KEYWORDS
acute hypoxemic respiratory failure, COVID-19, high-flow nasal cannula, oxygen support, SARS-CoV-2, spontaneous pneumomediastinum

1 | INTRODUCTION

The novel coronavirus (SARS-CoV-2) infection can lead to refractory hypoxemic respiratory failure and acute respiratory distress syndrome with possible fatal outcome. Patients can significantly benefit from high-flow nasal cannula (HFNC) oxygen therapy. We report herein a case of pneumomediastinum, which could be a rare complication of HFNC, as well as of SARS-CoV-2 pneumonia. The patient, an 89-year-old woman without known conditions predisposing to pneumomediastinum, was admitted for SARS-CoV-2 pneumonia. During the following days, the patient conditions worsened notwithstanding the respiratory support and treatment applied; therefore, we decided to start oxygen therapy with HFNC. Despite respiratory improvement, the patient began to complain of chest pain, which increased with respiratory acts and radiated to the neck, especially along the left side. After diagnosis of pneumomediastinum, was made HFNC was suspended and a low-flow system with nasal cannulas was started. Patient conditions progressively improved with clinical and radiological resolution of pneumomediastinum; subsequently, the patient completely recovered and was discharged COVID-19 free. To our best knowledge, this is the second case of pneumomediastinum in a COVID-19 patient after HFNC. From a review of similar cases and pathogenetic hypothesis, we can conclude that pneumomediastinum was caused by a combination of many factors (such as viral infection, cytokine storm, increase in transalveolar pressure due to cough, and possibly HFNC). Since pneumomediastinum is a severe complication, it is important to perform a prompt diagnosis, while treatment guidelines should define what is the best approach for oxygen support in COVID-19 patients.

SARS-CoV-2 is a new coronavirus responsible for coronavirus disease 2019 (COVID-19), which originated in the...
city of Wuhan, Hubei Province, Central China, and spreading quickly as a pandemic. This disease has many clinical presentations; indeed, it may be asymptomatic or it may present with typical symptoms such as fever, shortness of breath, cough, and loss of taste or with atypical presentations such as altered mental status, diarrhea, and nausea. In severe diseases, septic shock, acute respiratory distress syndrome (ARDS), difficult-to-correct metabolic acidosis, and coagulation dysfunction develop rapidly.

The virus replicates rapidly upon entry into alveolar epithelial cells, and triggers a strong immune response, resulting in a cytokine storm syndrome and pulmonary tissue damage. Cytokine storm syndrome is a group of disorders characterized by the uncontrolled production of pro-inflammatory cytokines, causing ARDS. Increased cytokines are released, such as interleukin (IL)-6, and various acute-phase reactants can lead to endothelial injury. Also, immobilization and hypercoagulable state due to elevated circulating prothrombotic factors, which are all elements/items included in Virchow’s triad, can explain the high risk of coagulopathy.

Multiple patchy ground-glass opacities with peripheral distribution are typical chest features of the COVID-19 pneumonia at computerized tomography (CT). These findings are mainly seen in the early stages of COVID-19 pneumonia and may be attributed to alveolar swelling, exudation in the alveolar space, and alveolar septal inflammation. Spontaneous pneumomediastinum is an uncommon but usually benign and self-limiting condition which most often occurs with chest pain, sometimes combined with dyspnea. This complication is generally caused by sudden increase in the thoracic pressure where the air dissects along the bronchovascular structures into the mediastinum resulting in alveolar rupture. Pulmonary diseases and smoking may also predispose to this condition. The precipitating factors may be forceful coughing or sneezing, but also several pulmonary infections (reviewed below in the paper). It is conceivable that SARS-CoV-2, which infects both type I and II pneumocytes, may cause breakdown of the integrity of the alveolar membrane, thus leading to alveolar rupture both via direct and indirect mechanisms mediated by hyperinflammation.

Severe COVID-19 often progresses to acute hypoxemic respiratory failure requiring high fractional concentration of inspired oxygen (FiO2). High-flow nasal cannula (HFNC) has emerged as a strategy improving oxygenation and carbon dioxide clearance. Through this procedure, the patient inspiratory demands were fulfilled by delivering up to 60 L/min of gas flow with an FiO2 up to 1.0, thus decreasing adverse outcomes, including the risk of dispersion of aerosolized particles relative to other techniques such as invasive ventilation. However, since COVID-19 is a new entity, it is important to study efficacy and possible adverse events of HFNC more in depth.

We report herein a case of pneumomediastinum which occurred in a patient suffering from SARS-CoV-2 pneumonia and acute hypoxemic respiratory failure treated with HFNC. We also provided a review of other reported cases of pneumomediastinum in patients with COVID-19.

2 | CASE PRESENTATION

The patient was an 89-year-old woman, who never smoked. She was admitted to our ward complaining of dry cough, which later became productive accompanied by shortness of breath. A nasal pharyngeal swab for PCR detecting SARS-CoV-2 RNA resulted positive. No underlying pulmonary diseases were known before COVID-19.

On admission, physical examination showed decreased breath sound, diffuse systolic murmur, and time-space disorientation. Respiratory rate was 26 acts per minute. Her hemato-biochemical examinations were unremarkable. Arterial oxygen saturation (SpO2) was 85% at rest in ambient air. She began therapy with low-flow oxygen support at 7 L/min. An hour later, arterial blood gas analysis (ABG) showed a P/F ratio of 250 indicating mild respiratory failure. Since the patient was not compliant with nasal cannula, which was self-removed several times, SpO2 deteriorated, so a Venturi Mask with FiO2 60% was positioned. Follow-up ABG showed P/F ratio of 153. Chest X-rays performed on the same day of admission showed diffuse interstitial thickening (Figure 1).

The patient was prescribed the following therapy: methylprednisolone, hydroxychloroquine, azithromycin, enoxaparin, and n-acetyl cysteine.

On the 4th day of hospitalization, the patient conditions worsened notwithstanding the respiratory support and treatment applied, with a P/F ratio of 85.5. Therefore, we decided to start oxygen therapy with HFNC (FiO2: 72%,

FIGURE 1 Chest X-rays performed on the day of admission
flow: 40 L/min with SpO2: 96%). The same day, high-resolution CT scan documented widespread ground-glass opacities with diffuse interstitial thickening and crazy paving (Figure 2).

Respiratory function improved slightly under prolonged support with HFNC. In fact, P/F ratio was 126. Chest X-rays performed on the 14th day of hospitalization showed a small improvement if compared to the previous (Figure 3).

During the following days, the patient's conditions improved further, so FiO2 was titrated to 36%, maintaining SpO2 at 97%, keeping a flow of 45 L/min.

Despite this improvement, on the 21st day of hospitalization, the patient complained of dyspnea and chest pain, which increased with respiratory acts and radiated to the neck, especially along the left side. An electrocardiogram was performed, not supporting myocardial infarction, as well as cardiac enzymes which were normal. Physical examination showed decreased breath sounds; the percussion was hyperresonant with no evidence of coarse crackles excluding a pulmonary edema. PCR, procalcitonin, and WBC were negative, and there were no signs of bacterial pneumonia. Arterial oxygen saturation improved, so FiO2 was reduced down to 21%, maintaining a flow of 45 L/min. Due to dyspnea and D-dimer increase up to 1.02 mg/L (normal range: 0 to 0.55 mg/L) in the suspicion of thromboembolism as a possible differential diagnosis in our patient, we performed a CT scan, including the study of the pulmonary arteries. This examination showed extensive pneumomediastinum, subcutaneous emphysema, and pneumothorax without evidence of any embolisms (Figure 4). In the presence of pneumomediastinum and improvement of gas exchanges, we decided to use a low-flow system such as nasal cannulas. The patient maintained hemodynamic stability. After 1 month from the admission, the patient was eupneic without any signs of respiratory failure with good gas exchanges without oxygen support and chest pain also disappeared. High-resolution CT scan performed after 38 days of hospitalization documented complete resolution of the pneumomediastinum (Figure 5). The patient was therefore discharged in good conditions.

3 | CASE REVIEW OF THE LITERATURE

A systematic review of the literature for all relevant articles was performed using PubMed. Articles were limited to those published in the English language. The search strategy used the keywords and MeSH terms: “pneumomediastinum”, “mediastinal emphysema”, “COVID-19”, “SARS-CoV-2”.

Up to the date of submission of the present manuscript, a total of 41 cases of pneumomediastinum have been reported in patients suffering from COVID-19, whose characteristics are summarized in Table 1. Among these 41 patients, 18 (44%) had been previously treated with invasive mechanical ventilation and one with noninvasive ventilation (NIV), thus suggesting a possible iatrogenic nature of pneumomediastinum. Only in one case, pneumomediastinum occurred in a patient after HFNC but subsequently increased in extent with pneumothorax occurring after NIV. In the remaining cases reported so far, pneumomediastinum appeared to occur independently from mechanical ventilation (Table 1).
4 | DISCUSSION

We present herein a case of pneumomediastinum in a patient with acute respiratory failure related to COVID-19. The patient was treated with HFNC, which appeared to be beneficial, but nonetheless, it could have triggered pneumomediastinum. To our best knowledge, this is the second case of pneumomediastinum occurring after HFNC in a COVID-19 patient (see Table 1). However, it is difficult to attribute pneumomediastinum to a single cause in our patient.

Spontaneous pneumomediastinum is defined as air in the mediastinum without evident causes (eg, traumatic, iatrogenic, hollow organ perforation, gas-producing infection surgery, or any other interventions). Numerous reports have demonstrated that several lung infections, mainly influenza, provoke pneumomediastinum. Radiological features are different in influenza pneumonia compared with COVID-19 and pneumomediastinum is believed to be a much less frequent complication (or never occurs) in COVID-19 pneumonia. By contrast, our case report indicates that it may occur, albeit this complication may have been favored by HFNC and other conditions.

Although pneumomediastinum was reported as a complication of several lung infections, it is possible that alterations induced by SARS-CoV-2 infection are more complex. For instance, SARS-CoV-2 infects both type I and II pneumocytes, and this may cause damage of the integrity of the alveolar membrane, which may lead to alveolar rupture. Moreover, in addition to a direct damage provoked by SARS-CoV-2 infection, indirect mechanisms due to cytokine storm or micro- and macrothrombosis events may play a role. It is currently unknown whether the increase in the transalveolar pressure during COVID-19 is greater than that occurring during other infections.

Mechanisms of action of HFNC are original and complex. In fact, HFNC delivers a mixture of air and oxygen, heated and humidified, at a higher flow than the patient's inspiratory peak. Thus, a further withdrawal of air from outside is not necessary to adjust the flow administered and required by the patient, contrary to what is obtained with low-flow systems. Consequently, the only inhaled oxygen mixture is that coming from the nasal cannulas. Therefore, the oxygen concentration (FiO2) set on the device corresponds to that inhaled by the subject. Furthermore, HFNC displays a beneficial effect on CO2 washout at high flow rates and on the alveolar recruitment. As a form of oxygen support, HFNC is considered to be safe and gentler than mechanical ventilation when used in adults with moderate hypoxemia.
FIGURE 5  High-resolution computerized tomography performed after 38 days of hospitalization, 17 days after the onset of pneumomediastinum

TABLE 1  Summary of cases of pneumomediastinum in patients with COVID-19

| Age (years) | Gender | Respiratory support prior to pneumomediastinum | Treatment | Outcome | Reference |
|-------------|--------|-----------------------------------------------|-----------|---------|-----------|
| 23          | F      | None                                          | Azithromycin Chloroquine | Positive | Kolani et al6 |
| 38          | M      | HFNC prior to pneumomediastinum and then NIV  | /         | Not reported | Sun et al9 |
| 38          | M      | Oxygen                                        | Moxifloxacin Ribavirin methylprednisolone Theophylline ambroxol Cefoperazone-tazobactam Recombinant human interferon alpha-1b via aerosol | Positive | Zhou et al10 |
| 64          | M      | Oxygen via nasal cannula                      | Not reported | Positive | Goldman et al11 |
| 30          | M      | Not reported                                  | Not reported | Positive | Romano et al12 |
| 65          | M      | Not reported                                  | Not reported | Positive | |
| 84          | F      | Oxygen mask with reservoir                    | Hydroxychloroquine Ceftriaxone Methylprednisolone | Negative | Vegas et al13 |
| 67          | M      | Oxygen mask                                   | Piperacillin/tazobactam Azithromycin | Negative | |
| 73          | M      | Oxygen mask with reservoir prior to pneumomediastinum, and then CPAP | Hydroxychloroquine Azithromycin Tocilizumab Methylprednisolone | Negative | |

(Continues)
| Age (years) | Gender | Respiratory support prior to pneumomediastinum | Treatment | Outcome<sup>a</sup> | Reference |
|------------|--------|---------------------------------------------|----------|---------------------|-----------|
| 49         | M      | Non-rebreather oxygen mask                  | Ceftriaxone doxycycline steroids Enoxaparin sodium Hydroxychloroquine | Positive | Mohan et al<sup>14</sup> |
| 65         | M      | Oxygen via nasal cannula or oxygen mask with reservoir | Azithromycin Hydroxychloroquine | Positive | Gorospe et al<sup>15</sup> |
| 60         | M      | Hydroxychloroquine, Lopinavir/ritonavir Tocilizumab Steroids | Hydroxychloroquine Azithromycin Lopinavir/Ritonavir Tocilizumab | Negative | |
| 62         | F      | Hydroxychloroquine Azithromycin Lopinavir/Ritonavir Tocilizumab | Hydroxychloroquine Azithromycin Lopinavir/ritonavir Tocilizumab | Positive | |
| 58         | F      | Hydroxychloroquine Azithromycin Lopinavir/ritonavir Tocilizumab | Hydroxychloroquine Azithromycin Lopinavir/ritonavir Tocilizumab | Positive | |
| 55         | F      | Oxygen mask with reservoir                  | Azithromycin Ceftriaxone Hydrocortisone | Negative | Quincho-Lopez et al<sup>16</sup> |
| 31         | M      | Oxygen nasal cannula                        | Azithromycin Ceftriaxone Hydrocortisone | Positive | |
| Not reported | Not reported | 10 patients: Mechanical ventilation | Not reported | Negative | Eperjesiova et al<sup>17</sup> |
| Not reported | Not reported | 5 patients without Oxygen support, of which 3 required eventually mechanical ventilation | Not reported | 4 positive 1 negative | |
| 36         | M      | After the onset of pneumomediastinum: Mechanical ventilation Pronation Veno-venous extracorporeal membrane oxygenation | Azithromycin Vitamin C Zinc sulfate Hydroxychloroquine Tocilizumab Solumedrol | Negative | Al Azzawi et al<sup>18</sup> |
| 47         | M      | Non-rebreather oxygen mask High-flow nasal cannula Mechanical ventilation Pronation | Hydroxychloroquine Azithromycin Zinc sulfate Tocilizumab | Positive | |
| 78         | M      | Mechanical ventilation                      | Hydroxychloroquine Azithromycin Zinc sulfate Norepinephrine | Negative | |
| 67         | M      | High-flow nasal cannula Mechanical ventilation Pronation | Antibiotics Antivirals Vasoconstrictors | Negative | Xiang et al<sup>19</sup> |
| Median (range) age was 60 years (38-70 years) | M | 5 patients: Mechanical ventilation | Not reported | 2 Negatives 3 Positives | Wali et al<sup>20</sup> |
| 36         | F      | Oxygen mask NIV                            | Antivirals Anti-inflammatory drugs | Negative | Wang et al<sup>21</sup> |

<sup>a</sup>The outcome is considered to be positive when the patient survived and negative when the patient died.
and Vianello et al. tested HFNC in patients with severe hypoxic acute respiratory failure consequent to SARS-CoV-2 infection, suggesting its safety for less severe patients. However, they were rarely reported, pneumothorax and pneumomediastinum are possible complications of HFNC even in non–COVID-19 patients.

An increased gradient of pressure in the alveoli compared with the lung interstitium was described as a possible mechanism by Makclin et al. Following rupture of the alveolar membrane, air penetrates into the interstitium, first causing interstitial emphysema, subsequently reaching the pulmonary hilum, and eventually provoking pneumomediastinum. This can happen when the intra-alveolar pressure increases or when the pressure in the interstitium decreases. The former mechanism occurs in those conditions mimicking the Valsalva maneuver, such as coughing or sneezing, while the latter mechanism occurs during extreme respiratory effort, marijuana smoking, diabetic ketosis, or rapid reduction in atmospheric pressure. In our patient, not only HFNC but also coughing could explain the increase in intra-alveolar pressure. In other terms, we cannot exclude that pneumomediastinum was from cough-induced barotrauma rather than from HFNC in our patient. It is, however, possible that, in patients with a more severe alveolar damage due to SARS-CoV-2 infection, and with precipitating factors such as cough, HFNC increases the risk of pneumomediastinum.

Lastly, we performed a review of patients with pneumomediastinum and found that approximately half of the cases were mechanically ventilated and half were not (see Table 1), possibly indicating that mechanical ventilation is a main risk factor, while HFNC may be better tolerated. Mediastinal emphysema and pneumothorax are well-known complications of mechanical ventilation. In fact, positive pressure mechanical ventilation may lead to pulmonary barotrauma due to elevation of the transalveolar pressure which is the difference in pressure between the alveolar pressure and the pressure in the interstitial space.

Volutrauma is referred to an excessive strain and may occur when tidal volume is set above 12 mL/kg predicted body weight, but decreases in tidal volume below 6 mL/kg, as proposed for “ultraprotective ventilation,” would not necessarily be of benefit. It has to be seen whether, with increasing amount of patients under observation and increasing utilization of HFNC, pneumomediastinum will appear with more frequency. Also, further studies should determine what impact HFNC will have compared with different techniques of respiratory support and with different patient conditions.

5 | CONCLUSIONS

We described herein a case of pneumomediastinum in a COVID-19 patient who was treated with HFNC. Several mechanisms could explain the occurrence of pneumomediastinum in our patient, as well as in other cases reported so far. So, we question whether it is appropriate to define such cases of pneumomediastinum as truly “spontaneous.” Oxygen support with HFNC is gentler than mechanical ventilation and may provide significant benefits, but more studies are needed to investigate the efficacy and safety of different respiratory supports in patients with COVID-19 pneumonia in order to provide more evidence-based recommendations. Moreover, it is important to recognize that an alternate to HFNC in COVID-19 patients, to prevent pneumomediastinum, may not be feasible because both HFNC and ventilation strategies increase the risk of barotrauma and alveolar rupture.

Meanwhile, a prompt diagnosis of pneumomediastinum should be made if chest pain and/or dyspnea occur in these patients, since this may have a great impact on patient prognosis.

ACKNOWLEDGEMENTS

We want to thank all our patients and our nurses. We also want to thank the Infectious Diseases and Tropical Medicine (IDTM) of the University “Magna Graecia” (UMG) COVID-19 Group, which is composed of, other than the main authors, the following: Bruno Tassone, Eugenio Arrighi, Graziella Perri, Paolo Fusco, Vincenzo Scaglione, Rosaria Lionello, Valentina La Gamba, Giuseppina Marrazzo, Maria Teresa Busceti, Amerigo Giudice, Marco Ricchio, Francesco Saverio Costanzo, Daniela Patrizia Foti, Giovanni Matera, Domenico Laganà, Bernardo Bertucci, Angela Quirino, Giorgio Settimo Barreca, Aida Giancotti, Luigia Gallo, Angelo Lamberti, Maria Carla Liberto, Nadia Marascio, and Adele Emanuela De Francesco. Published with written consent of the patient.

CONFLICT OF INTEREST

All authors declare that they have no conflict of interest in the publication of this paper. This study did not receive any specific grants from any funding agencies in the public, commercial, and nonprofit sectors. Dr Maria Mazzitelli was supported as PhD student by European Commission (FESR FSE 2014-2020) and by Calabria Region (Italy). European Commission and Calabria Region cannot be held responsible for any use, which may be made of information contained therein.

AUTHOR CONTRIBUTIONS

Anna Cancelliere and Giada Procopio: wrote the original draft, conceptualized the study, designed the methodology, and performed data curation. Elena Lio: designed the methodology and performed data curation. Maria Mazzitelli, Maria Petullà, Francesca Serapide, Maria Chiara, Pelle, and Chiara Davoli: performed data curation. Enrico Maria Treccarichi, Carlo Torti: reviewed the manuscript and supervised the study.
ETHICAL APPROVAL
Local Ethical Committee approved retrospective collection of data and patient signed informed consent for publication.

DATA AVAILABILITY STATEMENT
All available data are reported in the present manuscript.

ORCID
Anna Cancelliere https://orcid.org/0000-0002-2280-5753

REFERENCES
1. Li H, Liu S-M, Yu X-H, Tang S-L, Tang C-K. Coronavirus disease 2019 (COVID-19): current status and future perspective. Int J Antimicrob Agents. 2020;55:e105951. https://doi.org/10.1016/j.ijantimicag.2020.105951
2. Singhania N, Bansal S, Singhania G. An atypical presentation of novel coronavirus disease 2019 (COVID-19). Am J Med. 2020;133(7):e365-e366. https://doi.org/10.1016/j.ajmed.2020.03.026
3. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-539. https://doi.org/10.1007/s00281-017-0629-x
4. Singhania N, Bansal S, Nimmatoori DP, Ejaz AA, McCullough PA, Singhania G. Current overview on hypercoagulability in COVID-19. Am J Cardiovasc Drugs. 2020;20(5):393-403. https://doi.org/10.1007/s40256-020-00431-z. PMID: 32748336; PMCID: PMC7398761
5. Xu X, Yu C, Qu J, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging. 2020;47:1-6. https://doi.org/10.1007/s00259-020-04735-9
6. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-422. https://doi.org/10.1016/S2213-2600(20)30076-X
7. Ødegård K, Haavardsholm E, Husby A. Spontan pneumomediastinum. Tidsskrift for Den norske legeforening. 2018;138:e0132. https://doi.org/10.4045/tidsskr.18.0132
8. Kolani S, Houari N, Haloua M, et al. Spontaneous pneumomediastinum occurring in the SARS-COV-2 infection. IDCases. 2020;21:e00806. https://doi.org/10.1016/j.idcr.2020.e00806
9. Gralinski LE, Baric RS. Molecular pathology of emerging coronavirus infections. J Pathol. 2015;235(2):185-195. https://doi.org/10.1002/path.4454
10. Agarwal A, Basmaj J, Mudgal F, et al. High-flow nasal cannula for acute hypoxic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. Les canules nasales à haut débit pour le traitement de l’insuffisance respiratoire hypoxémique aiguë chez les patients atteints de la COVID-19: comptes rendus systématiques de l’efficacité et des risques d’aérosolisation, de dispersion et de transmission de l’infection. Canadian J Anesthesia/J Canadien d’Anesthésie. 2020;67(9):1217-1248. https://doi.org/10.1007/s12630-020-01740-2
11. Sun R, Liu H, Wang X. Mediastinal emphysema, giant bulla, and pneumothorax developed during the course of COVID-19 pneumonia. Korean J Radiol. 2020;21(5):541. https://doi.org/10.3348/kjr.2020.0180
12. Zhou C, Gao C, Xie Y, Xu M. COVID-19 with spontaneous pneumomediastinum. Lancet Infect Dis. 2020;20(4):510. https://doi.org/10.1016/S1473-3099(20)30156-0
13. Goldman N, Ketheeswaran B, Wilson H. COVID-19-associated pneumomediastinum. Clin Med. 2020;20(4):e91-e92. https://doi.org/10.7861/cclinmed.2020-0247
14. Romano N, Fischetti A, Melani EF. Pneumomediastinum related to Covid-19 pneumonia. Am J Med Sci. 2020;360(6):e19-e20. https://doi.org/10.1016/j.amjms.2020.06.003
15. Vega J, Gordo M, Tascón A, Vélez S. Pneumomediastinum and spontaneous pneumothorax as an extrapulmonary complication of COVID-19 disease. Emerg Radiol. 2020;27(6):727-730. https://doi.org/10.1007/s10140-020-01806-0
16. Mohan V, Tauseen R. Spontaneous pneumomediastinum in COVID-19. BMJ Case Rep. 2020;13:e236519. https://doi.org/10.1136/bcr-2020-236519
17. Gorospe L, Ayala-Carbonero A, Ureña-Vacas A, et al. Neumomediastino espontáneo en pacientes con COVID-19: una serie de cuatro casos. Arch Bronconeumol. 2020;56(11):754-756. https://doi.org/10.1016/j.arbes.2020.06.008
18. Quincho-Lopez A, Quincho-Lopez D, Hurtado-Medina F. Case report: pneumothorax and pneumomediastinum as uncommon complications of COVID-19 pneumonia—literature review. Am J Tropical Med Hygiene. 2020;103(3):1170-1176. https://doi.org/10.4269/ajtmh.20-0815
19. Eperjesiowa B, Hart E, Shokr M, Sinha P, Ferguson G. Spontaneous pneumomediastinum/pneumothorax in patients with COVID-19. Cureus. 2020;12:e8996. https://doi.org/10.7759/cureus.8996
20. Mohammed AA, Steven D, Abbas A, Ghadier A, John M. Spontaneous subcutaneous emphysema and pneumomediastinum in COVID-19 patients: an indicator of poor prognosis? Am J Case Rep. 2020;21:e925557. https://doi.org/10.12659/ AJCR.925557
21. Xiang C, Wu G. SARS-CoV-2 pneumonia with subcutaneous emphysema, mediastinal emphysema, and pneumothorax: a case report. Medicine. 2020;99:e20208. https://doi.org/10.1097/MD.00000000000020208
22. Walli A, Rizzo V, Billè A, Routledge T, Chambers A. Pneumomediastinum following intubation in COVID-19 patients: a case series. Anaesthesia. 2020;75(8):1076-1081. https://doi.org/10.1111/anae.15113
23. Wang J, Su X, Zhang T, Zheng C. Spontaneous pneumomediastinum: a probable unusual complication of coronavirus disease 2019 (COVID-19) pneumonia. Korean J Radiol. 2020;21:627. https://doi.org/10.3348/kjr.2020.0281
24. Chekkoth SM, Supreeth RN, Valsala N, Kumar P, Raja RS. Spontaneous pneumomediastinum in H1N1 infection: uncommon complication of a common infection. J R Coll Physicians Edinb. 2019;49(4):298-300. https://doi.org/10.4997/JRCPE.2019.409
25. Zhang X, Wang J, Zeng Q, Wu X, Jiang S, Shen J. Spontaneous pneumomediastinum and subcutaneous emphysema in avian influenza A (H5N6) human pneumonia. Clin Case Rep. 2019;7(12):2594-2595. https://doi.org/10.1002/ccr3.2519
26. López-Rivera F, Colón Rivera X, González Monroig HA, García PJ. Pneumomediastinum and pneumothorax associated with Herpes Simplex Virus (HSV) pneumonia. Am J Case Rep. 2018;19:109-113. https://doi.org/10.12659/AJCR.906051
27. Yeşilbaş O, Kihtr HS, Talip Petmezci M, et al. Bokavirus bronchiolitisinın çok nadir ve yaygıdı tehdit eden kompleksyoni-
ları: Pnönomediastinum ve bilateral pnömotoraks [Very rare and
life-threatening complications of bocavirus bronchiolitis: pneu-
mediastinum and bilateral pneumothorax]. Mikrobiyol Bul.
2016;50(1):159-164. https://doi.org/10.5578/mb.10312

28. Padhy AK, Gupta A, Aiyer P, Hajjiria NS, Grover V, Gupta VK.
Spontaneous pneumomediastinum: a complication of swine flu.
Asian Cardiovasc Thorac Ann. 2015;23(8):998-1000. https://doi.
org/10.11171/218492315585907

29. Xu W, Liu CF, Zhao Y, et al. Findings in children severely infected
with a novel influenza A virus of swine origin: pulmonary imaging.
World J Pediatr. 2012;8(3):240-246. https://doi.org/10.1007/
s12519-012-0364-2

30. Yoshinobu T, Abe K, Shimizu H, Yokoyama M, Osawa M, Hiraishi
Y. CT findings in pediatric novel influenza A (H1N1)-associated
pneumonia. Iran J Pediatr. 2012;22(2):213-217.

31. Jo BS, Lee IJ, Im HJ, Lee K. High-resolution computed tomography
findings of swine-origin influenza A (H1N1) virus (S-OIV) infec-
tion: comparison with scrub typhus. Acta Radiol. 2012;53(6):657-
661. https://doi.org/10.1258/ar.2012.120012

32. Patra PK, Nayak US, Sushma TS. Spontaneous pneumomediastin-
um in H1N1 infection. Indian Pediatr. 2011;48(12):976-977.

33. Bedolla-Barajas M, Hernández-Colín DD, Miramontes-Luna
E, Aguilera-Arreola JE, Bernal-López C, Robles-Figueroa M.
Neumomediastino espontáneo asociado a exacerbación delasma
durante la epidemia de influenza A H1N1; informe de cuatro casos
[Spontaneous pneumomediastinum associated witexacerbation of
asthma during the epidemic of influenza A H1N1: Inform of four
cases]. Rev Alerg Mex. 2011;58(3):142-146.

34. Yoo SY, Kim JH, Eo H, et al. H1N1 influenza infection in children:
frequency, pattern, and outcome of chest radiographic abnormal-
ities. Clin Radiol. 2011;66(4):334-339. https://doi.org/10.1016/j.
crard.2010.10.015

35. Chen SH, Huang IA, Wu CT, Hsia SH, Hung PC, Chiu CH.
Spontaneous pneumomediastinum and bilateral pneumothorax
in H1N1 virus infection. J CM. 2010;23(8):1897-1900. https://doi.
org/10.11171/1469-0691.2009.03086.x

36. Shim SS, Kim Y, Ryu YJ. Novel influenza A (H1N1) infection:
chest CT findings from 21 cases in Seoul, Korea. Clin Radiol.
2011;66(2):118-124. https://doi.org/10.1016/j.crard.2010.07.011

37. Harrod CC, Boykin RE, Kim YJ. Epideral pneumatoasis of the cer-
vicothoracic spine associated with transient upper motor neuron
findings complicating Haemophilus influenzae pharyngitis, bron-
chitis, and mediastinitis. J Pediatr Orthop. 2010;30(5):455-459.
https://doi.org/10.1097/BPO.0b013e3181df44b6

38. Hasegawa M, Hashimoto K, Morozumi M, Ubukata K, Takahashi
T, Inamo Y. Spontaneous pneumomediastinum complicating pneu-
momia in children infected with the 2009 pandemic influenza A
(H1N1) virus. Clin Microbiol Infect. 2010;16(2):195-199. https://
doi.org/10.1111/j.1469-0691.2009.03086.x

39. Tutor JD, Montgomery VL, Eid NS. A case of influenza virus
bronchiolitis complicated by pneumomediastinum and substutane-
ous emphysema. Pediatr Pulmonol. 1995;19(6):393-395. https://
doi.org/10.1002/ppul.1950190614

40. She WH, Chok KSH, Li IWS, et al. Pneumocystis jirovecii-related
spontaneous pneumothorax, pneumomediastinum and subcutane-
ous emphysema in a liver transplant recipient: a case report.
BMC Infect Dis. 2019;19(1):66. https://doi.org/10.1186/s1287
9-019-3723-y

41. Fantacci C, Ferrara P, Franceschi F, Chiaretti A. Pneumopericardium,
pneumomediastinum, and pneumorrhachis complicating acute re-
spiratory syncytial virus bronchiolitis in children. Eur Rev Med
Pharmacol Sci. 2017;21(15):3465-3468.

42. Ali HS, Hassan IF, George S. Extra corporeal membrane oxygen-
atation to facilitate lung protective ventilation and prevent ventilator-
induced lung injury in severe Pneumocystis pneumonia with
pneumomediastinum: a case report and short literature review.
BMC Pulm Med. 2016;16(1):52. https://doi.org/10.1186/s1289
0-016-0214-4. Published 2016 Apr 14

43. Huang L, Chen H, Peng S. Spontaneous pneumomediastinum,
emphysema, and pulmonary bullae associated with refractory
Mycoplasma pneumoniae pneumonia in a child. Pediatr Pulmonol.
2017;52(10):E77-E80. https://doi.org/10.1002/ppul.23761

44. Monaco F, Barone M, Manfredi VG, et al. Pneumomediastinum as
a complication of critical pertussis. Clin Respir J. 2016;10(6):772-
776. https://doi.org/10.1111/crj.12285

45. Pelican S, Gokturb K, Uygur Kucukapan H, Arslan U, Findik D.
Spontaneous pneumomediastinum as a complication in human
bocavirus infection. Pediatr Int. 2014;56(5):793-795. https://doi.
org/10.1111/ped.12475

46. Cheng WL, Ko WC, Lee NY, et al. Pneumomediastinum in patients
with AIDS: a case report and literature review. Int J Infect Dis.
2014;22:31-34. https://doi.org/10.1016/j.ijid.2013.12.009

47. Inamo Y, Ishizuka Y, Hashimoto K, et al. A 7-year-old girl with
subcutaneous emphysema, pneumomediastinum, pneumothorax,
and pneumoretroperitoneum caused by Mycoplasma pneumoniae
pneumonia. J Infect Chemother. 2012;18(2):247-250. https://doi.
org/10.1016/s1015-6666-011-03017

48. Ursic T, Steyer A, Kopriva S, Kalan G, Krivec U, Petrovec M.
Human bocavirus as the cause of a life-threatening infection. J
Clin Microbiol. 2011;49(3):1179-1181. https://doi.org/10.1128/JCM.
02362-10

49. Lee JC, Bell DC, Guinness RM, Ahmad T. Pneumocystis ji-
roveci pneumonia and pneumomediastinum in an anti-TNFalpha
naive patient with ulcerative colitis. World J Gastroenterol.
2009;15(15):1897-1900. https://doi.org/10.3748/wjg.15.1897

50. Vázquez JL, Vázquez I, González ML, García-Tejedor JL,
Repáraz A. Pneumomediastinum and pneumothorax as present-
ing signs in severe Mycoplasma pneumoniae pneumonia. J Pediatr
Pulmonol. 2007;37(12):1286-1288. https://doi.org/10.1002/ppul.7-
007-0611-1

51. Farrow D, Hesketh EL, Mitchell AE, Grimwood K. Mycoplasma
pneumoniae infection complicated by pneumomediastinum and
severe mucositis. J Paediatr Child Health. 2007;43(5):403-405.
https://doi.org/10.1111/j.1440-1754.2007.01088.x
55. Moss S, Carey PB, Hind CR. Pneumocystis carinii pneumonia presenting with pneumomediastinum in an HIV-positive patient. *Postgrad Med J*. 1995;71(832):96-97. https://doi.org/10.1136/pgmj.71.832.96

56. Villalona-Calero MA, Schrem SS, Phelps KR. Pneumomediastinum complicating Pneumocystis carinii pneumonia in a patient with AIDS. *Am J Med Sci*. 1989;297(5):328-330. https://doi.org/10.1097/00000441-198905000-00011

57. Onigbinde SO, Ojo AS, Fleary L, Hage R. Chest computed tomography findings in COVID-19 and influenza: a narrative review. *Biomed Res Int*. 2020;2020:e6928368. https://doi.org/10.1155/2020/6928368

58. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. *J Thromb Thrombolysis*. 2020;50(1):54-67. https://doi.org/10.1007/s11239-020-02134-3

59. Drake M. High flow nasal cannula oxygen in adults: an evidence-based assessment. *Ann Am Thorac Soc*. 2017;15:145-155. https://doi.org/10.1513/AnnalsATS.201707-548FR

60. Frat JP, Coudroy R, Marjanovic N, Thille AW. High-flow nasal oxygen therapy and noninvasive ventilation in the management of acute hypoxemic respiratory failure. *Ann Transl Med*. 2017;5(14):297. https://doi.org/10.21037/atm.2017.06.52

61. Sztrymf B, Messika J, Bertrand F, et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study. *Intensive Care Med*. 2011;37:1780-1786. https://doi.org/10.1007/s00134-011-2354-6

62. Sztrymf B, Messika J, Mayot T, Lenglet H, Dreyfuss D, Ricard J-D. Impact of high-flow nasal cannula oxygen therapy on intensive care unit patients with acute respiratory failure: a prospective observational study. *J Crit Care*. 2011;26:324.e9-324.e13. https://doi.org/10.1016/j.jcrc.2011.07.075

63. Andrea V, Arcaro G, Molena B, et al. High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection. *Thorax*. 2020;75(11):998-1000. https://doi.org/10.1136/thoraxjnl-2020-214993

64. Sonobe S, Inoue S, Nishiwada T, Egawa J, Kawaguchi M. A case of subcutaneous emphysema/mediastinal emphysema during the use of humidified high-flow nasal cannula. *JA Clinical Reports*. 2019;5:85. https://doi.org/10.1186/s40981-019-0305-3

65. Baudin F, Gagnon S, Crulli B, Proulx F, Jouvet P, Emeriaud G. Modalities and complications associated with the use of high-flow nasal cannula: experience in a pediatric ICU. *Respiratory Care*. 2016;61:1305-1310. https://doi.org/10.4187/respcare.04452

66. Hegde S, Prodhan P. Serious air leak syndrome complicating high-flow nasal cannula therapy: a report of 3 cases. *Pediatrics*. 2013;131:e939-e944. https://doi.org/10.1542/peds.2011-3767

67. Macklin MT, Macklin CC. Malignant interstitial emphysema of the lungs and mediastinum as an important occult complication in many respiratory diseases and other conditions: interpretation of the clinical literature in the light of laboratory experiment. *Medicine*. 1944;23:281-358. https://doi.org/10.1043/29.wjr.v6.i11.850

68. Conti V, Mascetti S, Avoscan C, et al. Prolonged valsalva. A case of spontaneous pneumomediastinum (Hamman’s syndrome). *Rassegna Patol dell’Apparato Respiratorio*. 2014;29:269-272.

69. Maunder RJ, Pierson DJ, Hudson LD. Subcutaneous and mediastinal emphysema: pathophysiology, diagnosis and management. *Arch Intern Med*. 1984;144:1447-1453. https://doi.org/10.1001/archinte.1984.00350190143024

70. Diaz R, Heller D. Barotrauma and mechanical ventilation. [Updated 2020 Jun 30]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2020 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545226/

71. Coutinho L, Marini JJ, Collino F, et al. The future of mechanical ventilation: Lessons from the present and the past. *Crit Care*. 2017;21:183. https://doi.org/10.1186/s13054-017-1750-x

72. Perna V, Vilà E, Guelbenzu JJ, Amat I. Pneumomediastinum: is this really a benign entity? When it can be considered as spontaneous? Our experience in 47 adult patients. *Eur J Cardiothorac Surg*. 2010;37(3):573-575. https://doi.org/10.1016/j.ejcts.2009.08.002

73. Kouritas VK, Papagiannopoulos K, Lazaridis G, et al. Pneumomediastinum. *J Thorac Dis*. 2015;7(Suppl 1):S44-S49. https://doi.org/10.3978/j.issn.2072-1439.2015.01.11

74. Li XP, Zhang L, Li L, Yang B, Zhang WD. Idiopathic tension mediastinal emphysema cured by video-assisted thoracic surgery: a case report. *Int J Clin Exp Med*. 2015;8(10):19601-19603. Published 2015 Oct 15.

How to cite this article: Cancelliere A, Procopio G, Mazzitelli M, et al. A case report of pneumomediastinum in a COVID-19 patient treated with high-flow nasal cannula and review of the literature: Is this a “spontaneous” complication?. *Clin Case Rep*. 2021;9:e04007. https://doi.org/10.1002/ccr3.4007